ClinicalTrials.gg
CompletedNCT06333860IMMpactfulUpdated Apr 15, 2026

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

A Phase 4 interventional study of Risankizumab and Deucravacitinib in Moderate Plaque Psoriasis, sponsored by AbbVie. Completed at 88 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
6th of 30
393 · median 162
Started
2024
the only one that year
Phase 4
7 of 30
1 open now
Registered
29th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 6th largest by enrollment, is the only one that started in 2024, is one of 7 in phase 4, and was the 29th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly.

This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants

Participants will be administered subcutaneous (SC) treatment of risankizumab every 12 weeks for up to 44 weeks or provided deucravacitinib oral tablets to be taken once daily.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Moderate Plaque Psoriasis

Browse trials for

Keywords

  • risankizumab
  • deucravacitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with a diagnosis of chronic plaque psoriasis (PsO) with or without psoriatic arthritis, for at least 6 months prior to Baseline.
  • Stable moderate chronic plaque psoriasis at both Screening and Baseline as defined as:

    • Body Surface Area (BSA) ≥ 10% and ≤ 15%,
    • Psoriasis Area and Severity Index (PASI) ≥ 12, and
    • Static Physician Global Assessment (sPGA) = 3 (moderate) based on a 5-point scale (0 to 4).
  • Participant must be a candidate for systemic therapy as assessed by the investigator
  • Psoriasis inadequately controlled by topicals, phototherapy and/or systemic treatments (including, but not limited to, methotrexate, apremilast, cyclosporine A, , and/or cyclophosphamide)

Exclusion criteria

Exclusion Criteria:

  • Participants with any form of PsO other than chronic plaque PsO (e.g., pustular PsO, palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic, or guttate PsO).
  • Participants with a history of current drug-induced PsO or a drug-induced exacerbation of preexisting PsO.
  • Participants with a history of active ongoing inflammatory skin diseases other than PsO (with or without PsA) that could interfere with the assessment of PsO (e.g., hyperkeratotic eczema).
  • Participants with a history of severe renal insufficiency defined as \< 30 mL/min and/or requiring hemodialysis or peritoneal dialysis.
  • Participantswith a history of (per investigator's judgment) drug or alcohol abuse within the last 6 months.
  • Participants with a history of an allergic reaction or significant sensitivity to constituents of the study drugs (and its ) and/or other products in the same class.
  • Participants who have had major surgery performed within 12 weeks prior to randomization or planned during the conduct of the study (e.g., hip replacement, aneurysm removal, stomach ligation).
  • Participants with evidence of:

virus (HBV) or virus (HCV) infection, defined as:

  • HBV: Hepatitis B surface antigen (HBs Ag) positive (+) test or detected sensitivity on the HBV DNA PCR qualitative test for subjects who are hepatitis B core antibody (HBc Ab) positive (+) (and for hepatitis B surface antibody [HBs Ab] positive [+] participants where mandated by local requirements).
  • HCV: HCV RNA detectable in any participant with anti-HCV antibody (HCV Ab).
  • (HIV), defined as confirmed positive anti-HIV Ab test and considered to have unstable disease (Unless meeting criteria for stable disease) Participants with HIV with no history of AIDS-defining conditions AND stable disease for at least 6 months prior to screening can be enrolled. Criteria for stable disease is achieved if all below criteria are met. Documentation of "stable disease" can be done at the Screening visit or by documentation of labs performed within 1 month of the Randomization visit, in addition to the subject's medical history.
  • On stable antiretroviral therapy;
  • Viral load (HIV RNA) below the lower limit of quantification by a validated and approved plasma HIV-1 RNA quantitative assay;
  • ≥ 500 cells/μL.

    - Participants with any of the following medical diseases or disorders:

  • Recent (within past 6 months) cerebrovascular accident or myocardial infarction;
  • History of an organ transplant which requires continued ;
  • Active or suspected or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
  • Prior history of suicide attempt at any time in the subject's lifetime prior to signing the and randomization, or major depression or suicidal ideation or attempt requiring hospitalization within the last 3 years prior to signing the informed consent.
  • Hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

    - Participants who received within 30 days prior to Baseline any:

  • Other systemic immunomodulating treatments (including, but not limited to:

    e.g., methotrexate, apremilast, cyclosporine A, , cyclophosphamide, tofacitinib [Xeljanz®]);

  • Other systemic PsO treatments (e.g., retinoids, fumarates, any other drug known to possibly benefit PsO);
  • Photochemotherapy (e.g., PUVA), phototherapy (e.g., UVB) or prolonged exposure or use of tanning booths or ultraviolet light sources.

    • Participants who received within 14 days prior to Baseline any topical treatment for PsO or any other skin condition (including, but not limited to: e.g., corticosteroids, vitamin D analogues, vitamin A analogues, pimecrolimus, retinoids, salicyl vaseline, salicylic acid, lactic acid, tacrolimus, tar, urea, or anthralin).
    • Participants who have been treated with any strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin, St. John's Wort) within 30 days or 5 half-lives of start of treatment with deucravacitinib.
    • Participants who received any live viral or bacterial vaccine within 4 weeks prior to the first dose of study drug, or expect the need for during study participation including at least 147 days (21 weeks or as guided by the local risankizumab label [if approved], whichever is longer) after the last dose of risankizumab or at least 30 days after the last dose of deucravacitinib.
    • Participants who have been treated with any drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or be currently enrolled in another interventional clinical study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    Period A: Arm 1 Risankizumab Dose A

    Participants will be centrally randomized at the Baseline (Day 1) visit to receive Risankizumab as a single SC injection

    Drug: Risankizumab

  • Experimental
    Period A: Arm 2 Deucravacitinib Dose A

    Participants will be centrally randomized at the Baseline (Day 1) visit to receive Deucravacitinib orally once per day until the day prior to Week 16

    Drug: Deucravacitinib

  • Experimental
    Period B: Arm 2a Risankizumab Dose A (Continued)

    Participants initially randomized to risankizumab (Arm 1) will continue to receive risankizumab as a single SC injection at Weeks 16, 28, and 40

    Drug: Risankizumab

  • Experimental
    Period B: Arm 2b Deucravacitinib Dose A

    Participants initially randomized to Deucravacitinib (Arm 2) will be re-randomized at the Week 16 visit to receive Deucravacitinib orally once per day up to Week 52

    Drug: Deucravacitinib

  • Experimental
    Period B: Arm 2a Risankizumab Dose A

    Participants initially randomized to Deucravacitinib (Arm 2) will be re-randomized at the Week 16 visit to receive Risankizumab as a single SC injection at Weeks 16, 20, 32, and 44

    Drug: Risankizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Period A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90)

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: At Week 16

  2. Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) with at least 2-grade improvement from Baseline

    The static Physicians Global Assessment (sPGA) is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA composite score ranges from 0 to 4 and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

    Time frame: Baseline, Week 16

  3. Period B: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) in the Intent to Treat Population for non-responders in Period B (ITT_B_NR).

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: At Week 52

  4. Number of Participants Experiencing Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

    Time frame: Baseline up to 73 Weeks

Secondary outcomes

  1. Period A: Percentage of Participants Achieving 100% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 100)

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as at least a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: At Week 16

  2. Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 with at least 2-grade improvement from Baseline

    The static Physicians Global Assessment (sPGA) is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA composite score ranges from 0 to 4 and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

    Time frame: Baseline. Week 16

  3. Period B: Percentage of Participants Achieving 100% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 100) among participants in the ITT_B_NR Population

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as at least a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: At Week 52

  4. Period B: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 with at least 2-grade improvement from Baselineamong participants in the ITT_B_NR Population.

    The static Physicians Global Assessment (sPGA) is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA composite score ranges from 0 to 4 and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

    Time frame: At Week 52

07

Study locations

88 sites
  • Total Skin and Beauty Dermatology Center /ID# 263011
    Birmingham, Alabama 35205, United States
  • Advanced Research Associates - Glendale /ID# 263621
    Glendale, Arizona 85308, United States
  • Clear Dermatology & Aesthetics Center /ID# 263626
    Scottsdale, Arizona 85260, United States
  • Dermatology Trial Associates /ID# 264480
    Bryant, Arkansas 72022, United States
  • First OC Dermatology /ID# 263003
    Fountain Valley, California 92708, United States
  • Integrative Skin Science and Research /ID# 264504
    Sacramento, California 95815, United States
  • Physioseq, LLC /ID# 265035
    Sacramento, California 95825, United States
  • Medderm Associates Dermatology /ID# 263858
    San Diego, California 92103, United States
  • Southern California Dermatology /ID# 263021
    Santa Ana, California 92701, United States
  • Clearlyderm Dermatology - West Boca /ID# 264963
    Boca Raton, Florida 33428, United States
  • Driven Research /ID# 263002
    Coral Gables, Florida 33134, United States
  • Skin Care Research - Hollywood /ID# 263877
    Hollywood, Florida 33021-6748, United States
  • International Dermatology Research /ID# 264911
    Miami, Florida 33144, United States
  • Lenus Research and Medical Group /ID# 263886
    Miami, Florida 33172, United States
  • Wellness Clinical Research - Miami Lakes /ID# 263887
    Miami Lakes, Florida 33016, United States
  • Skin Care Research - Tampa /ID# 263880
    Tampa, Florida 33607-6438, United States
  • Advanced Clinical Research Institute /ID# 263878
    Tampa, Florida 33607, United States
  • University Dermatology and Vein Clinic, LLC /ID# 263028
    Chicago, Illinois 60640-7972, United States
  • Arlington Dermatology /ID# 263001
    Rolling Meadows, Illinois 60008, United States
  • Dawes Fretzin, LLC /ID# 264578
    Indianapolis, Indiana 46256, United States
  • MetroBoston Clinical Partners /ID# 263860
    Boston, Massachusetts 02135-3511, United States
  • University of Michigan Health System - Ann Arbor /ID# 265233
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan - Clinton Township Office /ID# 264968
    Clinton Township, Michigan 48038, United States
  • Dermatology and Skin Center of Lees Summit /ID# 263560
    Lee's Summit, Missouri 64064-2301, United States
  • Physician Research Collaboration, LLC /ID# 263568
    Lincoln, Nebraska 68516, United States
  • Skin Cancer and Dermatology Institute - Reno /ID# 263697
    Reno, Nevada 89509, United States
  • StracSkin, PLLC /ID# 263024
    Portsmouth, New Hampshire 03801, United States
  • Oregon Dermatology & Research Center /ID# 263674
    Portland, Oregon 97210, United States
  • Clinical Partners /ID# 263862
    Johnston, Rhode Island 02919, United States
  • Health Concepts /ID# 263016
    Rapid City, South Dakota 57702, United States
  • Arlington Research Center, Inc /ID# 263908
    Arlington, Texas 76011, United States
  • Bellaire Dermatology Associates /ID# 263897
    Bellaire, Texas 77401, United States
  • U.S. Dermatology Partners - Cedar Park /ID# 263906
    Cedar Park, Texas 78613, United States
  • Dermatology Treatment and Research Center /ID# 267071
    Dallas, Texas 75230, United States
  • Texas Dermatology Research Center /ID# 264487
    Plano, Texas 75025, United States
  • Dermatology Clinical Research Center of San Antonio /ID# 263869
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies - Clear Lake /ID# 263009
    Webster, Texas 77598, United States
  • Center for Clinical Studies - Clear Lake /ID# 263917
    Webster, Texas 77598, United States
  • Premier Clinical Research /ID# 263679
    Spokane, Washington 99202, United States
  • Paratus Clinical Research Woden /ID# 263120
    Phillip, Australian Capital Territory 2606, Australia
  • Premier Dermatology /ID# 263119
    Kogarah, New South Wales 2217, Australia
  • The Skin Hospital - Sydney /ID# 263634
    Sydney, New South Wales 2010, Australia
  • Veracity Clinical Research /ID# 263091
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute /ID# 263116
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology - Melbourne /ID# 262997
    East Melbourne, Victoria 3002, Australia
  • Cliniques Universitaires UCL Saint-Luc /ID# 263106
    Brussels, Brussels Capital 1200, Belgium
  • UZ Gent /ID# 263107
    Ghent, Oost-Vlaanderen 9000, Belgium
  • CHU de Liege /ID# 263108
    Liège, 4000, Belgium
  • Dermatology Research Institute - Blackfoot Trail /ID# 264476
    Calgary, Alberta T2J 7E1, Canada
  • Beacon Dermatology Inc /ID# 264266
    Calgary, Alberta T3A 2N1, Canada
  • Wiseman Dermatology Research /ID# 265317
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Toronto Dermatology Centre /ID# 264273
    Toronto, Ontario M3H 5Y8, Canada
  • Private Practice - Dr. Kim Papp Clinical Research /ID# 264269
    Waterloo, Ontario N2J 1C4, Canada
  • Private Practice - Dr. Angelique Gagne-Henley /ID# 264267
    Saint-Jérôme, Quebec J7Z 7E2, Canada
  • Universitaetsklinikum Freiburg /ID# 263069
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Hautarztpraxis Langenau /ID# 263070
    Langenau, Baden-Wurttemberg 89129, Germany
  • Beldio Research GmbH /ID# 263073
    Memmingen, Bavaria 87700, Germany
  • Dermatologie Mahlow /ID# 263072
    Blankenfelde-Mahlow, Brandenburg 15831, Germany
  • Fachklinik - Bad Bentheim /ID# 263066
    Bad Bentheim, Lower Saxony 48455, Germany
  • Universitaetsklinikum Muenster /ID# 263061
    Münster, North Rhine-Westphalia 48149, Germany
  • Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 263955
    Berlin, 10117, Germany
  • University General Hospital Attikon /ID# 263421
    Athens, Attica 12462, Greece
  • General Hospital Andreas Syggros /ID# 263418
    Athens, Attica 16121, Greece
  • General Hospital Andreas Syggros /ID# 263708
    Athens, Attica 16121, Greece
  • Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 263419
    Thessaloniki, 54643, Greece
  • Papageorgiou General Hospital /ID# 263414
    Thessaloniki, 56429, Greece
  • Debreceni Egyetem-Klinikai Kozpont /ID# 263484
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Derm-surg /ID# 263799
    Kaposvár, Somogy County 7400, Hungary
  • Semmelweis Egyetem /ID# 263483
    Budapest, 1085, Hungary
  • UNO Medical Trials /ID# 263478
    Budapest, 1135, Hungary
  • Szegedi Tudomanyegyetem /ID# 263800
    Szeged, 6720, Hungary
  • IRCCS Istituto Clinico Humanitas /ID# 263466
    Rozzano, Lombardy 20089, Italy
  • Duplicate_Azienda Ospedaliera Universitaria Federico II /ID# 264034
    Naples, Napoli 80131, Italy
  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 263986
    Bologna, 40138, Italy
  • Azienda Ospedaliero Universitaria Pisana /ID# 263468
    Pisa, 56126, Italy
  • Amsterdam UMC, locatie AMC /ID# 263550
    Amsterdam, North Holland 1105 AZ, Netherlands
  • Spaarne Gasthuis - Hoofddorp /ID# 263165
    Hoofddorp, North Holland 2134 TM, Netherlands
  • Private Practice - Dr. Alma Cruz /ID# 263212
    Carolina, 00985, Puerto Rico
  • Pan American Center for Oncology Trials /ID# 263206
    Rio Piedras, 00935, Puerto Rico
  • Clinical Research Puerto Rico /ID# 263213
    San Juan, 00909-1711, Puerto Rico
  • GCM Medical Group, PSC /ID# 263198
    San Juan, 00917, Puerto Rico
  • Mindful Medical Research /ID# 263201
    San Juan, 00918-3756, Puerto Rico
  • Hospital General Universitario de Alicante Doctor Balmis /ID# 262977
    Alicante, 03010, Spain
  • Hospital Clinic de Barcelona /ID# 263040
    Barcelona, 08036, Spain
  • Hospital Universitario de La Princesa /ID# 262980
    Madrid, 28006, Spain
  • Victoria Hospital /ID# 262984
    Kirkcaldy, Fife KY2 5AH, United Kingdom
  • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 262981
    London, Greater London E1 2ES, United Kingdom
  • Northern Care Alliance NHS Group /ID# 262983
    Salford, M6 8HD, United Kingdom
08

References and documents

Publications

  • Magnolo N, Soung J, Frew J, Costanzo A, Ruiz-Santiago H, Eyerich K, Llamas-Velasco M, Bukhalo M, Sivamani RK, Moore A, Wu T, Xie J, Patel M, Ashley D, Kaplan B, Stakias V, Espaillat R, Warren RB. Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. Dermatol Ther (Heidelb). 2026 Jul;16(7):3415-3429. doi: 10.1007/s13555-026-01779-x. Epub 2026 May 17. PubMed 42143644 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Mar 2026, 22 months.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 22 months is close to that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 27, 2024
StartActual
May 10, 2024
Primary completionActual
Mar 19, 2026
CompletionActual
Mar 19, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06333860
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
May 10, 2024
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026
Last update
Apr 15, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risankizumab · Deucravacitinib

Start the discussion